Experimental Drug Shows Promise and is Currently Being Investigated as a Treatment for Alzheimer's
One of the biggest problems we are facing in finding an effective treatment for Alzheimer’s is the lack of participation by qualified patients in clinical trials.
It is my belief that caregivers should be investigating and participating in Phase III clinical trials for Alzheimer’s disease. If we don’t participate actively it will take longer than is necessary to find a treatment for Alzheimer’s that works.
Alzheimer's Reading Room
The benefits to the people living with Alzheimer’s are great when participating in a clinical trial.
This includes not only testing to determine the stage of the disease, but also medical testing to determine overall health. This study is testing an adjunctive therapy, which allows your loved one to take the study drug with Donepezil (Aricept), Rivastigmine (Exelon) or Galantamine (Razadyne).
The phase II clinical trial highlighted here shows promise and could result in an effective drug for AD. Right now, the study is seeking qualified Alzheimer’s patients for its Phase III clinical trial. Could this be the one?
The phase III clinical trial (Star Studies) is now open and recruiting new patients. If you are interested in finding out if you loved one is qualified to participate for this clinical trial go here, or click on the image above.
The phase III study will have the following:
- All study-related medicines and consultations specific to the study will be free of charge and reasonable travel, parking and food expenses will be paid
- The patient may continue to see their regular doctor while participating in this study
- Health insurance is not required to participate in this study
- A high standard of study-related medical care will be provided
- Patients may help to advance a potential new treatment for mild to moderate Alzheimer’s disease
- Patient may have an opportunity to continue in a 6-month extension
Source of information and to learn more about the Phase II clinical trial- http://investor.lundbeck.com/releasedetail.cfm?ReleaseID=796082
This is a sponsored article - Access to Patients